Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT07559890
Recruiting Not applicable

Monopolar Basivertebral Nerve Ablation for Axial Low Back Pain

NCT07559890 · tracked via the Priya Life Science Sweden tracker
Sponsor
EPC Education s.r.o
Phase
Not applicable
Started
2026-05-04
Last updated
2026-07-31

Condition(s) studied

Chronic Back PainBasivertebral Nerve Ablation

Investigational drug(s) / intervention(s)

BVN ablation

BVN ablation: intraosseal monopolar basivertebral nerve ablation

Study summary

Determination of efficacy and safety of Monopolar Basivertebral Nerve Ablation for Axial Low Back Pain treatment, including the method optimization.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Axial low back pain (with or without lateral component). * Presence of Modic type I or II changes at ≥ 1 level. * Age over 18 years. * Duration of pain ≥ 6 months. * Completion of full conservative management for ≥ 3 months. * Medial Branch Block (MBB) test performed with negative results/ or Facet Denervation done with unsatisfactory outcome (less than 50% improvement) after positive MBB test. Exclusion Criteria: * Coagulation disorders. * Platelet abnormalities. * Lack of informed consent. * Generalized solid tumor. * Hematopoietic malignancy. * Radicular pain. * Alternative primary pain generators other than axial low back pain. * Previous spinal surgery. * Targeted level located above L3/L4 * Osteoporosis

Primary outcome measure(s)

  • The Oswestry Disability Index (ODI) — 6 weeks, and 3, 6, 12 months
    Scale 0-100%; a lower score indicates minimal disability, while a higher score indicates greater disability.

Trial sites (3)

FacilityCityRegionStatus
EuroPainClinics Praha a.s Prague Czechia Recruiting
Poliklinika Terasa Košice Slovakia Not Yet Recruiting
Europainclinics Sweden Umeå Sweden Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07559890 on ClinicalTrials.gov ↗ ← All trials in Sweden